Literature DB >> 26663021

Noninvasive fatty liver markers predict liver disease mortality in the U.S. population.

Aynur Unalp-Arida1, Constance E Ruhl2.   

Abstract

UNLABELLED: Nonalcoholic fatty liver disease (NAFLD) contributes to premature death along with obesity, diabetes, and cardiovascular disease (CVD). We examined whether hepatic steatosis (HS) on ultrasound and liver enzyme activities were associated with increased liver disease mortality in the U.S. National Health and Nutrition Examination Survey (NHANES), 1988-1994, with up to 23 years of linked-mortality data. Survey-linked National Death Index records were analyzed among 14,527 adult participants who were negative for viral hepatitis B and C and iron overload. HS on ultrasound was categorized as normal, mild, moderate, or severe. Alanine aminotransferase (ALT), aspartate aminotransferase (AST), and gamma-glutamyltransferase (GGT) elevation was defined as the highest sex-specific decile. Cumulative mortality was 36.2% from all causes, including 16.3% from CVD, 10.8% from cancer, 5.4% from diabetes, and 1.1% from liver disease. Severe HS was associated with increased liver disease mortality in both age-adjusted (hazard ratio [HR]: 3.92; 95% confidence interval [CI]: 1.49-10.27; P for trend: 0.011) and multivariate-adjusted analyses (HR, 2.68; 95% CI: 1.02-7.03; P for trend: 0.072). HS was not independently associated with mortality from all causes, CVD, cancer, or diabetes. Higher liver disease mortality was found with elevated ALT (HR, 4.08; 95% CI: 1.99-8.33), AST (HR, 4.33; 95% CI: 2.18-8.59), and GGT (HR, 7.91; 95% CI: 3.06-20.46). GGT elevation was associated with increased overall mortality (HR, 1.45; 95% CI: 1.21-1.74). Liver enzymes were otherwise unrelated to overall or cause-specific mortality.
CONCLUSIONS: In the U.S. population, severe hepatic steatosis on ultrasound and liver enzyme elevation were associated with increased liver disease mortality, but were not independently associated with mortality from all causes (except for GGT), CVD, cancer, or diabetes.
© 2015 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26663021      PMCID: PMC4805455          DOI: 10.1002/hep.28390

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  40 in total

Review 1.  Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease.

Authors:  Giovanni Targher; Christopher P Day; Enzo Bonora
Journal:  N Engl J Med       Date:  2010-09-30       Impact factor: 91.245

2.  PNPLA3 variants specifically confer increased risk for histologic nonalcoholic fatty liver disease but not metabolic disease.

Authors:  Elizabeth K Speliotes; Johannah L Butler; Cameron D Palmer; Benjamin F Voight; Joel N Hirschhorn
Journal:  Hepatology       Date:  2010-09       Impact factor: 17.425

3.  The association of low serum alanine aminotransferase activity with mortality in the US population.

Authors:  Constance E Ruhl; James E Everhart
Journal:  Am J Epidemiol       Date:  2013-09-26       Impact factor: 4.897

4.  Association between variants in or near PNPLA3, GCKR, and PPP1R3B with ultrasound-defined steatosis based on data from the third National Health and Nutrition Examination Survey.

Authors:  Ruben Hernaez; Jody McLean; Mariana Lazo; Frederick L Brancati; Joel N Hirschhorn; Ingrid B Borecki; Tamara B Harris; Thutrang Nguyen; Ihab R Kamel; Susanne Bonekamp; Mark S Eberhardt; Jeanne M Clark; Wen Hong Linda Kao; Elizabeth K Speliotes
Journal:  Clin Gastroenterol Hepatol       Date:  2013-02-13       Impact factor: 11.382

5.  The association of genetic variability in patatin-like phospholipase domain-containing protein 3 (PNPLA3) with histological severity of nonalcoholic fatty liver disease.

Authors:  Yaron Rotman; Christopher Koh; Joseph M Zmuda; David E Kleiner; T Jake Liang
Journal:  Hepatology       Date:  2010-09       Impact factor: 17.425

6.  Homozygosity for the patatin-like phospholipase-3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease.

Authors:  Luca Valenti; Ahmad Al-Serri; Ann K Daly; Enrico Galmozzi; Raffaela Rametta; Paola Dongiovanni; Valerio Nobili; Enrico Mozzi; Giancarlo Roviaro; Ester Vanni; Elisabetta Bugianesi; Marco Maggioni; Anna Ludovica Fracanzani; Silvia Fargion; Christopher P Day
Journal:  Hepatology       Date:  2010-04       Impact factor: 17.425

7.  Prevalence of nonalcoholic fatty liver disease in the United States: the Third National Health and Nutrition Examination Survey, 1988-1994.

Authors:  Mariana Lazo; Ruben Hernaez; Mark S Eberhardt; Susanne Bonekamp; Ihab Kamel; Eliseo Guallar; Ayman Koteish; Frederick L Brancati; Jeanne M Clark
Journal:  Am J Epidemiol       Date:  2013-05-23       Impact factor: 4.897

8.  A new equation to estimate glomerular filtration rate.

Authors:  Andrew S Levey; Lesley A Stevens; Christopher H Schmid; Yaping Lucy Zhang; Alejandro F Castro; Harold I Feldman; John W Kusek; Paul Eggers; Frederick Van Lente; Tom Greene; Josef Coresh
Journal:  Ann Intern Med       Date:  2009-05-05       Impact factor: 25.391

9.  Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits.

Authors:  Elizabeth K Speliotes; Laura M Yerges-Armstrong; Jun Wu; Ruben Hernaez; Lauren J Kim; Cameron D Palmer; Vilmundur Gudnason; Gudny Eiriksdottir; Melissa E Garcia; Lenore J Launer; Michael A Nalls; Jeanne M Clark; Braxton D Mitchell; Alan R Shuldiner; Johannah L Butler; Marta Tomas; Udo Hoffmann; Shih-Jen Hwang; Joseph M Massaro; Christopher J O'Donnell; Dushyant V Sahani; Veikko Salomaa; Eric E Schadt; Stephen M Schwartz; David S Siscovick; Benjamin F Voight; J Jeffrey Carr; Mary F Feitosa; Tamara B Harris; Caroline S Fox; Albert V Smith; W H Linda Kao; Joel N Hirschhorn; Ingrid B Borecki
Journal:  PLoS Genet       Date:  2011-03-10       Impact factor: 5.917

10.  Non-alcoholic fatty liver disease and mortality among US adults: prospective cohort study.

Authors:  Mariana Lazo; Ruben Hernaez; Susanne Bonekamp; Ihab R Kamel; Frederick L Brancati; Eliseo Guallar; Jeanne M Clark
Journal:  BMJ       Date:  2011-11-18
View more
  35 in total

1.  Liver fibrosis scores predict liver disease mortality in the United States population.

Authors:  Aynur Unalp-Arida; Constance E Ruhl
Journal:  Hepatology       Date:  2017-05-16       Impact factor: 17.425

2.  Emerging new standard for non-invasive assessment of liver disease mortality in non-alcoholic fatty liver disease.

Authors:  Say-Yee Loo; Wah-Kheong Chan
Journal:  Hepatobiliary Surg Nutr       Date:  2017-04       Impact factor: 7.293

3.  The natural history of nonalcoholic fatty liver disease: mortality rates and liver enzymes.

Authors:  Carlos J Pirola; Silvia Sookoian
Journal:  Hepatobiliary Surg Nutr       Date:  2017-04       Impact factor: 7.293

4.  Magnetic Resonance Imaging Proton Density Fat Fraction Associates With Progression of Fibrosis in Patients With Nonalcoholic Fatty Liver Disease.

Authors:  Veeral Ajmera; Charlie C Park; Cyrielle Caussy; Seema Singh; Carolyn Hernandez; Ricki Bettencourt; Jonathan Hooker; Ethan Sy; Cynthia Behling; Ronghui Xu; Michael S Middleton; Mark A Valasek; Claire Faulkner; Emily Rizo; Lisa Richards; Claude B Sirlin; Rohit Loomba
Journal:  Gastroenterology       Date:  2018-04-13       Impact factor: 22.682

5.  Prevalence and Risk Factors of Cardiovascular Disease in Patients with Chronic Hepatitis B.

Authors:  Ho Soo Chun; Jae Seung Lee; Hye Won Lee; Beom Kyung Kim; Jun Yong Park; Do Young Kim; Sang Hoon Ahn; Seung Up Kim
Journal:  Dig Dis Sci       Date:  2021-09-02       Impact factor: 3.487

6.  Among Patients With Nonalcoholic Fatty Liver Disease, Modest Alcohol Use Is Associated With Less Improvement in Histologic Steatosis and Steatohepatitis.

Authors:  Veeral Ajmera; Patricia Belt; Laura A Wilson; Ryan M Gill; Rohit Loomba; David E Kleiner; Brent A Neuschwander-Tetri; Norah Terrault
Journal:  Clin Gastroenterol Hepatol       Date:  2018-03-14       Impact factor: 11.382

7.  Repeated liver stiffness measurement compared with paired liver biopsy in patients with non-alcoholic fatty liver disease.

Authors:  Sivesh K Kamarajah; Wah-Kheong Chan; Nik Raihan Nik Mustapha; Sanjiv Mahadeva
Journal:  Hepatol Int       Date:  2018-01-25       Impact factor: 6.047

Review 8.  Mechanisms of Fibrosis Development in Nonalcoholic Steatohepatitis.

Authors:  Robert F Schwabe; Ira Tabas; Utpal B Pajvani
Journal:  Gastroenterology       Date:  2020-02-08       Impact factor: 22.682

9.  Objectively measured sedentary time, physical activity and liver enzyme elevations in US Hispanics/Latinos.

Authors:  Jun Li; Simin Hua; Guo-Chong Chen; Garrett Strizich; Mark H Kuniholm; Zhilei Shan; Gregory A Talavera; Sheila F Castañeda; Marc D Gellman; Jianwen Cai; Scott J Cotler; Xuehong Zhang; Frank B Hu; Robert Kaplan; Carmen R Isasi; Qibin Qi
Journal:  Liver Int       Date:  2020-05-25       Impact factor: 5.828

10.  Factors to Consider in Development of Drugs for Pediatric Nonalcoholic Fatty Liver Disease.

Authors:  Miriam B Vos; Lara Dimick-Santos; Ruby Mehta; Stephanie O Omokaro; Johannes Taminiau; Elmer Schabel; David E Kleiner; Peter Szitanyi; Piotr Socha; Jeffrey B Schwimmer; Stephanie Noviello; Debra G Silberg; Richard Torstenson; Veronica Miller; Joel E Lavine
Journal:  Gastroenterology       Date:  2019-09-12       Impact factor: 22.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.